Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells. 2013

Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
Department of Burns and Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.

Saikosaponin A (SSA) is a major triterpenoid saponin isolated from Radix bupleuri (RB), a widely used Chinese traditional medicine to treat various inflammation-related diseases. The aim of this study was to investigate the anti-inflammatory activity, as well as the molecular mechanism of SSA in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. In this study, we demonstrated that SSA markedly inhibits the expression of certain immune-related cytotoxic factors, including cyclooxygenase-2 (COX-2) and inducible nitric-oxide synthase (iNOS), as well as pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6. It also significantly upregulates the expression of IL-10, an important anti-inflammatory cytokine, suggesting its anti-inflammatory activity in LPS-stimulated macrophages. We further demonstrated that SSA inhibits the activation of the nuclear factor-κB (NF-κB) signaling pathway by suppressing the phosphorylation of inhibitory NF-κB inhibitor α (IκBα) and thus holding p65 NF-κB in the cytoplasm to prevent its translocation to the nucleus. In addition, SSA also inhibits the mitogen-activated protein kinase (MAPK) signaling pathway by downregulating the phosphorylation of p38 MAPK, c-Jun N-terminal kinase (c-JNK) and extracellular signal-regulated kinase (ERK), the three key components of the MAPK family. In conclusion, our study demonstrates that SSA has an anti-inflammatory effect by regulating inflammatory mediators and suppressing the MAPK and NF-κB signaling pathways in LPS-stimulated RAW 264.7 cells.

UI MeSH Term Description Entries

Related Publications

Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
September 2021, Molecules (Basel, Switzerland),
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
January 2018, Mediators of inflammation,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
January 2014, International immunopharmacology,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
December 2014, Immunopharmacology and immunotoxicology,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
April 2019, International journal of molecular medicine,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
February 2020, BMB reports,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
December 2015, Journal of ethnopharmacology,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
November 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
January 2015, Evidence-based complementary and alternative medicine : eCAM,
Jie Zhu, and Chengqun Luo, and Ping Wang, and Quanyong He, and Jianda Zhou, and Hao Peng
January 2014, Evidence-based complementary and alternative medicine : eCAM,
Copied contents to your clipboard!